Docetaxel

País: Nova Zelanda

Idioma: anglès

Font: Medsafe (Medicines Safety Authority)

ingredients actius:

Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg

Disponible des:

REX Medical Ltd

Designació comuna internacional (DCI):

Docetaxel trihydrate 25.177 mg (equivalent to anhydrous docetaxel 20mg)

Dosis:

20 mg/mL

formulario farmacéutico:

Concentrate for infusion

Composición:

Active: Docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg Excipient: Citric acid Polysorbate 80 Ethanol Water for injection

Unidades en paquete:

Vial, glass, Diluent, 1.5 mL

clase:

Prescription

tipo de receta:

Prescription

Fabricat per:

Cipla Ltd

indicaciones terapéuticas:

Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. Docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express HER2 and who previously have not received chemotherapy for metastatic disease.

Resumen del producto:

Package - Contents - Shelf Life: Vial, glass, Diluent - 1.5 mL - 24 months from date of manufacture - Vial, glass, concentrate solution - 20 mg - 24 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze)

Data d'autorització:

2006-06-23